Tenofovir Alafenamide for Treatment of Symptoms and Neuroprotection in Relapsing Remitting Multiple Sclerosis

Exclusion Criteria

• •1. Pregnancy or lactation
• •2. Known allergic reactions to components of TAF
• •3. Treatment with another investigational drug or other MS-directed intervention such as glatiramer acetate, or dimethyl fumarate within 3 months
• •4. Positive HIV antibody test, active or latent hepatitis B
• •5. Relapse and/or steroid treatment within the previous 30 days
• •6. Baseline EDSS \> 7
• •7. Current symptoms of severe, progressive, or uncontrolled renal, hematologic, gastrointestinal, pulmonary, cardiac, or neurologic disease, or other medical conditions that, in the opinion of the Investigator, might place the subject at unacceptable risk for participation in this study
• •8. Known history of sleep apnea, narcolepsy, or other significant sleep disorders
• •9. Recent changes to medications affecting sleep or fatigue or changes in dosage of those medications within 90 days
• •10. Creatinine clearance (CrCl) \<55mL/min, as calculated by the Cockcroft-Gault equation
• •11. Taking medication with known interactions with tenofovir alafenamide including: Acyclovir, valacyclovir, adefovir, cabozantinib, carbamazepine, cidofovir, cladribine, cobicistat, diclofenac, multiple NSAIDs or chronic high dose NSAIDs, fosphenytoin or phenytoin, ganciclovir, valganciclovir, oxcarbazepine, phenobarbital, primidone, rifabutin, rifampin, rifapentine, sofosbuvir, tipranavir